Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBOLD Prostate-302: Risvutatug Rezetecan in mCRPC
NCT07802704Phase 3Recruiting
- Sponsor
- GSK
- Start
- Sep 2026
- Primary completion
- Dec 2029
- Countries
- 4
01
Overview
A Phase 3 trial of risvutatug rezetecan in metastatic castration-resistant prostate cancer (mCRPC), sponsored by GSK. Started Sep 2026; status: recruiting.
02
Drugs
risvutatug rezetecan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07802704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07802704.